Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
329 Leser
Artikel bewerten:
(2)

New Horizon Medical Solutions Announces the Acquisition of the Applied Tissue Technologies Business Assets

New Horizon Medical Solutions acquires transparent negative pressure wound therapy device and micro grafting kit to enhance its industry-leading portfolio of wound care solutions

LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / New Horizon Medical Solutions (NHMS) is excited to announce the acquisition of Applied Tissue Technologies' (ATT) business assets. ATT is a pioneering, 25-year-old wound care company based in Boston, Massachusetts. This strategic move aligns with NHMS's commitment to delivering cutting-edge products that enhance wound care management.

Key acquisition highlights

  • Novel wound technologies
    ATT has developed patented treatment methods and proprietary devices that empower caregivers to heal wounds more efficiently. Their technologies are designed for use in both established economic zones and in underserved areas, using non-powered and battery-powered solutions.

  • Expert leadership
    Elof Eriksson, MD, PhD, founder of ATT and a distinguished figure in the field of plastic and reconstructive surgery, has been instrumental in the development of these innovative products. He served as chief of plastic and reconstructive surgery at Brigham and Women's Hospital in Boston from 1986 to 2016 and held the prestigious Joseph E. Murray chair of plastic and reconstructive surgery at Harvard Medical School.

  • Revolutionary wound dressing
    Dr. Eriksson states, "We have developed a novel, simpler, and more predictable wound dressing that features a transparency unlike any other in the marketplace, which is what providers have been searching for."

Strategic vision

Will Hall, CEO of New Horizon Medical Solutions, remarked, "Together, these and other recent additions to our portfolio begin to distinguish us from others and make us a formidable industry partner." This acquisition not only expands NHMS's product offerings but also enhances its position as a leader in advanced wound care solutions.

About New Horizon Medical Solutions

New Horizon Medical Solutions (NHMS) is a leader in advanced wound care technologies, developing and delivering biologically derived human placental allograft products designed to meet the highest standards of safety, quality, and performance. The company's portfolio includes amniotic membranes, placental tissues, and skin graft solutions for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. NHMS has recently expanded its offerings to include advanced diagnostic imaging technologies through its partnership with Kent Imaging. Guided by evidence-based design, patient focus, and precision manufacturing, NHMS delivers solutions that support better clinical decision-making and improved patient outcomes.
www.nhmedical.com

About Applied Tissue Technologies

Applied Tissue Technologies brings advancements in wound healing to patients. This includes research and development supported by the United States Department of Defense to help wounded warriors at the point of injury, instances of prolonged field care and delayed evacuation, and continuing through advanced levels of military medical care. www.appliedtissue.com

Media contact?

Julian Rogers?
Director of Corporate Marketing?
New Horizon Medical Solutions
Julian.rogers@nhmedical.com
702-960-2913

SOURCE: New Horizon Medical Solutions



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/new-horizon-medical-solutions-announces-the-acquisition-of-the-applie-1121940

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.